C-OODUmitochondrial uncoupling, Controlled Metabolic Accelerators, oral medicines
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rivus Pharmaceuticals states that improving cardio-metabolic health requires developing controlled metabolic accelerators (CMAs) that target the underlying metabolic risk factors driving cardiovascular mortality and morbidity. The company presents this mechanism-focused approach as its core belief about how to achieve better health outcomes.
SourceRivus Pharmaceuticals states that poor cardio-metabolic health is driven by underlying metabolic dysfunction, especially the accumulation of fat and sugars in the body, and that improving cellular metabolism can reverse disease course. The company presents controlled metabolic accelerators (CMAs) as a new therapeutic approach that works with the body’s natural processes to restore energy balance, increase energy expenditure, and address root causes rather than only treating downstream effects of metabolic disease.
SourceRivus Pharmaceuticals states that obesity is a primary driver of cardio-metabolic disease and that reducing excess body fat can lower the risk of conditions such as heart failure, type 2 diabetes, dyslipidemia, and NAFLD/NASH. The company presents mitochondrial uncoupling as a natural metabolic process that can be harnessed in a measured way through its Controlled Metabolic Accelerators (CMAs) to selectively reduce fat throughout the body while preserving skeletal muscle mass, with the broader aim of enabling healthier lives for millions.
Source